Eribulin
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | HALAVEN | — | 2016-01-28 – 2022-09-13 | fda.gov ↗ |
| Approved | EU (EMA) | Halaven | — | 2011-03-17 | europa.eu ↗ |
| Approved | US (FDA) | HALAVEN | — | 2010-11-15 | fda.gov ↗ |
Trials 172 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT02338037 | May 2015 → Aug 2017 | metastatic malignant neoplasm in the brain, primary brain neoplasm | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 134 trials | ||||||
| Phase 1 | NCT06957431 | Oct 2025 → May 2031 expected | leiomyosarcoma, liposarcoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT06590558 | Aug 2025 → May 2027 | female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1 | NCT06006273 | Aug 2023 → Dec 2026 expected | refractory malignant neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05774886 | May → Sep 2023 | female breast carcinoma, triple-negative breast carcinoma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT04013217 | Jul 2019 → Mar 2022 | cancer | Health Hope Pharma | Terminated | No outcome recorded |
| Phase 1 | NCT03502681 | Jun 2018 → Oct 2019 | urothelial carcinoma | Monika Joshi, MD | Terminated | No outcome recorded |
| Phase 1 | NCT03579472 | May 2018 → Sep 2022 | female breast carcinoma, triple-negative breast carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT03430518 | May 2018 → Feb 2020 | Her2-receptor negative breast cancer, ovarian cancer | Amy Tiersten | Completed | No outcome recorded |
| Phase 1 | NCT03361436 | Mar 2018 → Feb 2023 overdue | liposarcoma, retroperitoneal cancer, scrotum cancer, spermatic cord cancer | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03207672 | Aug 2017 → Jul 2018 overdue | cancer | Eisai Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03056599 | Dec 2016 → Jul 2021 | soft tissue sarcoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02824575 | Jul 2016 → Dec 2021 | Her2-receptor negative breast cancer, breast adenocarcinoma | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT02616848 | Nov 2015 | triple-negative breast carcinoma | Istituti Ospitalieri di Cremona | Unknown | No outcome recorded |
| Phase 1 | NCT02596503 | Oct 2015 → Apr 2019 | refractory malignant neoplasm | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT02120469 | Oct 2014 → Mar 2019 | triple-negative breast carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02171260 | Jul 2014 → Jan 2016 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02082626 | Feb 2014 → Jun 2018 | childhood malignant neoplasm, lymphoma | University of Oklahoma | Terminated | No outcome recorded |
| Phase 1 | NCT02014337 | Jan 2014 → Dec 2017 | breast cancer, malignant epithelial tumor of ovary, non-small cell lung carcinoma, prostate cancer +2 | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01795586 | Feb 2013 → Feb 2015 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01945710 | Dec 2012 → Oct 2015 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01585870 | Jul 2012 → Sep 2015 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01432886 | Oct 2011 → Aug 2013 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03002493 | Dec 2009 → Feb 2011 | neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01106248 | Mar 2009 → Sep 2010 | neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00908908 | Mar 2009 → May 2011 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01000376 | Feb → Aug 2009 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00706095 | Feb 2008 → Sep 2009 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00415324 | Dec 2006 → May 2014 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00410553 | Nov 2006 → Oct 2012 | ovarian carcinoma, uterine corpus cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00268905 | Oct 2006 → Nov 2011 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00326950 | Jun 2006 → Jan 2008 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00069264 | Sep 2003 → Mar 2005 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00069277 | Aug 2003 → Apr 2005 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00047034 | Aug 2002 → Oct 2007 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/223 trials | ||||||
| Phase 1/2 | NCT07494448 | Jul 2026 → Dec 2027 expected | HER2 positive breast carcinoma | MedSIR | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06942234 | Jun 2025 → Jun 2027 expected | Her2-receptor negative breast cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05824975 | May 2023 → Nov 2025 overdue | Her2-receptor negative breast cancer, colorectal cancer, cutaneous melanoma, hepatocellular carcinoma +3 | GI Innovation, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06202261 | Apr 2023 → Dec 2026 expected | breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05335473 | May 2022 → May 2025 | Her2-receptor negative breast cancer | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05041101 | Dec 2021 → Sep 2024 | inflammatory breast carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04345913 | Mar 2021 → Mar 2024 overdue | female breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04078295 | Sep 2019 → Mar 2027 expected | neoplasm | Eisai Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04061863 | Aug 2019 → Apr 2022 | breast cancer | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03526679 | Jul 2018 → Jun 2021 | leiomyosarcoma, liposarcoma | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03424005 | Mar 2018 → Sep 2030 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03245450 | Mar 2018 → May 2021 | Ewing sarcoma, refractory malignant neoplasm, rhabdomyosarcoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02753595 | Jul 2016 → Aug 2019 | breast cancer | Eisai Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02513472 | Aug 2015 → Jul 2019 | breast neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02396433 | Apr 2015 | breast cancer | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01596751 | Jul 2012 → Jul 2017 | breast cancer | Hope Rugo, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT01744340 | May 2012 → Mar 2015 | colorectal cancer, head and neck cancer | Howard Safran | Completed | No outcome recorded |
| Phase 1/2 | NCT01554371 | Mar 2012 → Dec 2019 | breast carcinoma, peripheral neuropathy | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/2 | NCT01388647 | Aug 2011 → Jun 2014 | HER2 positive breast carcinoma | Vector Oncology | Terminated | No outcome recorded |
| Phase 1/2 | NCT01126736 | Jun 2010 → Dec 2012 | non-small cell lung carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01126749 | Apr 2010 → May 2015 | urinary bladder cancer | Eisai Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01323530 | Jan 2010 → Jul 2014 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00365157 | Oct 2006 → Jul 2025 overdue | urothelial carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 288 trials | ||||||
| Phase 2 | NCT07255612 | Nov → Dec 2026 expected | breast cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07520760 | Apr 2026 → Apr 2030 expected | Her2-receptor negative breast cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06889610 | Mar 2026 → Dec 2027 expected | colorectal cancer, melanoma, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07441512 | Mar 2026 → Mar 2028 expected | triple-negative breast carcinoma | Hu Hai | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07333937 | Dec 2025 → Nov 2027 expected | breast cancer | Xijing Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07205185 | Oct 2025 → Dec 2027 expected | soft tissue sarcoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07657130 | Jul 2025 → Jun 2026 overdue | female breast carcinoma | Liaoning Cancer Hospital & Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06678230 | Nov 2024 → Oct 2025 | breast cancer | The First Hospital of Jilin University | Unknown | No outcome recorded |
| Phase 2 | NCT06449222 | Aug 2024 → Aug 2028 expected | female breast carcinoma, triple-negative breast carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06533722 | Aug → Sep 2024 | Her2-receptor negative breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT06539559 | Aug 2024 → Feb 2026 overdue | breast cancer, metastatic neoplasm | Wang Jiayu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06387628 | Jul 2024 → Apr 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06308939 | Mar 2024 → Dec 2025 overdue | breast cancer | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06202313 | Feb 2024 → Dec 2025 overdue | triple-negative breast carcinoma | Shengjing Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05458674 | Jan 2024 → Jun 2027 expected | breast carcinoma by gene expression profile | Criterium, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05826964 | Jun 2023 → Jul 2026 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | University of Miami | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05810870 | May 2023 → Apr 2026 overdue | breast cancer | MedSIR | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05619913 | May 2023 → Mar 2025 overdue | ovarian carcinosarcoma, uterine carcinosarcoma | Australia New Zealand Gynaecological Oncology Group | Recruiting | No outcome recorded |
| Phase 2 | NCT05263882 | Mar 2022 → Dec 2023 | Her2-receptor negative breast cancer | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05945368 | Feb 2022 → Feb 2024 | HER2 positive breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05402722 | Jan → Dec 2022 | triple-negative breast carcinoma | Beijing 302 Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04502680 | Jun 2021 → Jun 2023 | triple-negative breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT04913571 | May 2021 → Jun 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04624711 | Mar 2021 → Jun 2022 | Her2-receptor negative breast cancer | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05206656 | Oct 2020 → Apr 2022 | breast cancer | Hunan Cancer Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04464174 | Oct 2020 → Nov 2023 | triple-negative breast carcinoma | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT04517292 | Oct 2020 → Jul 2022 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05546255 | Jun 2020 → Dec 2022 | triple-negative breast carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04303741 | Mar 2020 → Nov 2022 | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03840772 | Jul 2019 → Sep 2024 | solitary fibrous tumor | Italian Sarcoma Group | Completed | No outcome recorded |
| Phase 2 | NCT03899805 | Jun 2019 → Jul 2024 | leiomyosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT03637868 | Feb 2019 → Apr 2020 | breast cancer | Institut Paoli-Calmettes | Withdrawn | No outcome recorded |
| Phase 2 | NCT05833919 | Jul 2018 → Jul 2023 | breast cancer | Consorzio Oncotech | Unknown | No outcome recorded |
| Phase 2 | NCT03237780 | Jul 2018 → Jun 2027 expected | renal pelvis urothelial carcinoma, ureter cancer, urethra cancer, urinary bladder carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03441360 | Apr 2018 → Jan 2021 | Ewing sarcoma, rhabdomyosarcoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03810976 | Mar 2018 → May 2022 | sarcoma | Yonsei University | Completed | No outcome recorded |
| Phase 2 | NCT03331250 | Jan 2018 → Jul 2023 overdue | angiosarcoma, epithelioid hemangioendothelioma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03222856 | Dec 2017 → Oct 2018 | breast cancer | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT03032614 | Sep 2017 → Mar 2019 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer, ovarian cancer | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded |
| Phase 2 | NCT03202316 | Aug 2017 → Dec 2027 expected | inflammatory breast carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02788201 | Mar 2017 → Oct 2019 | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03051659 | Mar 2017 → Oct 2018 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT03412955 | Mar 2017 → Apr 2020 | breast cancer | Tan Tock Seng Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02640508 | May 2016 → Nov 2020 | cancer | Virginia G. Kaklamani | Completed | No outcome recorded |
| Phase 2 | NCT02623972 | Feb 2016 → May 2021 overdue | Her2-receptor negative breast cancer, inflammatory breast carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02581839 | Nov 2015 → Jul 2018 | breast cancer, metastatic malignant neoplasm in the brain | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02681523 | Oct 2015 → Jul 2018 | breast cancer | Imperial College London | Terminated | No outcome recorded |
| Phase 2 | NCT02404506 | Aug 2015 → Dec 2020 | adenocarcinoma, breast cancer | Swiss Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT02481050 | Jun 2015 → Dec 2016 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02263495 | Dec 2014 → May 2017 | breast cancer | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02178241 | Dec 2014 → Mar 2019 | carcinoma of urethra, renal pelvis/ureter urothelial carcinoma, ureter carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02215876 | Sep 2014 → Aug 2017 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 2 | NCT02175446 | Sep 2014 → Dec 2016 | Her2-receptor negative breast cancer | Consorzio Oncotech | Unknown | No outcome recorded |
| Phase 2 | NCT02097238 | Aug 2014 → Jun 2015 | osteosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01908101 | Jan 2014 → May 2019 | female breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT02000596 | Jan 2014 → Nov 2015 | breast cancer | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2 | NCT02035813 | Jan 2014 → Jan 2024 | hormone receptor-positive breast cancer | University of Ulm | Completed | No outcome recorded |
| Phase 2 | NCT01941407 | Nov 2013 → Aug 2014 | breast cancer | ARCAGY/ GINECO GROUP | Completed | No outcome recorded |
| Phase 2 | NCT01912963 | Sep 2013 → Dec 2016 | HER2 positive breast carcinoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT02061085 | Jul 2013 → Dec 2015 | breast neoplasm, metastatic neoplasm | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT01827787 | May 2013 → May 2016 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01698281 | Dec 2012 → Aug 2014 | breast cancer | AEterna Zentaris | Terminated | No outcome recorded |
| Phase 2 | NCT01705691 | Sep 2012 → Mar 2014 | Her2-receptor negative breast cancer, female breast carcinoma | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 2 | NCT01676818 | Aug 2012 → Feb 2021 | cervical carcinoma | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT01593020 | Aug 2012 → Nov 2020 | female breast carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01669252 | Aug 2012 → Jun 2015 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT01527487 | Jun 2012 → Sep 2014 | Her2-receptor negative breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01613768 | May 2012 → Aug 2017 | salivary gland cancer | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT01534455 | Feb 2012 → Mar 2015 | breast cancer | GBG Forschungs GmbH | Terminated | No outcome recorded |
| Phase 2 | NCT01498588 | Nov 2011 → Jun 2015 | breast cancer | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT01458249 | Nov 2011 → Nov 2014 | soft tissue sarcoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01401959 | Sep 2011 → Apr 2017 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01439282 | Aug 2011 → Nov 2012 | estrogen-receptor positive breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01372579 | Aug 2011 → Jun 2020 | male breast carcinoma, triple-negative breast carcinoma | Northwestern University | Unknown | No outcome recorded |
| Phase 2 | NCT01328249 | Mar 2011 → Oct 2014 | Her2-receptor negative breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01268150 | Feb 2011 → Mar 2012 | Her2-receptor negative breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01269346 | Dec 2010 → Mar 2013 | female breast carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01156753 | Jul 2010 → Oct 2012 | breast cancer | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00965523 | Jan 2008 → Dec 2010 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00413192 | Jan 2007 → Jun 2012 | soft tissue sarcoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00400829 | Nov 2006 → Jan 2011 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00337077 | Nov 2006 → Jun 2009 | hormone-resistant prostate carcinoma, prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00383760 | Aug 2006 → Jul 2011 | pancreatic adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00337129 | May 2006 → Aug 2008 | head and neck cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00334893 | Apr 2006 → Mar 2012 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00246090 | Oct 2005 → Sep 2007 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00100932 | Dec 2004 → Jun 2008 | non-small cell lung carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00097721 | Sep 2004 → Nov 2006 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT07088263 | Sep 2025 → Jul 2027 expected | breast neoplasm | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06889688 | Feb 2025 → Dec 2028 expected | triple-negative breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06382142 | Jun 2024 → Jun 2026 overdue | triple-negative breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06343948 | Apr 2024 → May 2026 overdue | hormone receptor-positive breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06072612 | Dec 2023 → Dec 2027 expected | breast cancer | BriaCell Therapeutics Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT03613181 | Dec 2023 → Dec 2024 | Her2-receptor negative breast cancer, malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain, neoplastic meningitis | Angiochem Inc | Unknown | No outcome recorded |
| Phase 3 | NCT05954442 | Sep 2023 → Aug 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06857305 | Jul 2023 → Jul 2026 | breast cancer | Ma Fei，MD | Unknown | No outcome recorded |
| Phase 3 | NCT05347134 | Jun 2022 → Nov 2023 overdue | triple-negative breast carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04579224 | Jun 2021 → Aug 2030 expected | urinary bladder carcinoma, urothelial carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03786094 | May 2019 → Oct 2021 | breast cancer | Spexis AG | Terminated | No outcome recorded |
| Phase 3 | NCT03264547 | Aug 2017 → Dec 2024 | breast cancer | Japan Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT02344472 | Sep 2015 → Jan 2025 | breast cancer | University of Ulm | Unknown | No outcome recorded |
| Phase 3 | NCT02037529 | Jan 2014 → Feb 2021 | Her2-receptor negative breast cancer, breast adenocarcinoma, invasive breast carcinoma | Academic and Community Cancer Research United | Suspended | No outcome recorded |
| Phase 3 | NCT02225470 | Sep 2013 → Sep 2017 | female breast carcinoma, triple-negative breast carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01454934 | Dec 2011 → May 2014 | non-small cell lung carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01327885 | Mar 2011 → Jan 2015 | soft tissue sarcoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00388726 | Nov 2006 → May 2009 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00337103 | Sep 2006 → Mar 2012 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05033769 | Mar 2021 → Jul 2023 | female breast carcinoma | Institut fuer Frauengesundheit | Unknown | No outcome recorded |
| Phase 4 | NCT03583944 | Mar 2018 → Jun 2019 | breast neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02864030 | May 2014 → Dec 2018 | breast cancer, poisoning, toxic polyneuropathy | Oncologia Medica dell'Ospedale Fatebenefratelli | Completed | No outcome recorded |
| Phase 4 | NCT01961544 | Jun 2013 → Jul 2015 | breast cancer | Eisai Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01142661 | Aug 2010 → Aug 2011 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01240421 | Mar 2011 → Mar 2015 | breast cancer | Eisai Inc. | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 70 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06328738 Background | May 2024 → Jan 2027 expected | HER2 positive breast carcinoma, colorectal cancer | Enliven Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02419495 Background | Jun 2015 → Sep 2024 | cutaneous melanoma, fallopian tube carcinoma, metastatic malignant neoplasm, metastatic melanoma +5 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01802970 Background | Dec 2012 → Jan 2017 | breast cancer | Baylor Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01418677 Comparator | Oct 2011 → Jul 2014 | cancer of unknown primary site | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06775236 Comparator | Mar 2025 → Jun 2027 expected | breast cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04826016 Background | Mar 2022 | breast cancer | MedSIR | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04711824 Background | Mar 2022 → Jul 2026 overdue | breast cancer, metastatic malignant neoplasm in the brain | Colette Shen | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02723877 Background | Mar 2016 → Oct 2018 | breast cancer | PIQUR Therapeutics AG | Completed | No outcome recorded |
| Phase 223 trials | ||||||
| Phase 2 | NCT07203729 Comparator | Mar 2026 → Jun 2030 expected | breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06875128 Background | Jan 2026 → May 2029 expected | — | Delcath Systems Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07007559 Background | Dec 2025 → Dec 2027 expected | breast cancer | ALX Oncology Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06731153 Background | Dec 2024 → Jun 2027 expected | triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06678048 Background | Oct 2024 → Apr 2026 overdue | breast cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06102824 Comparator | Oct 2024 → Jun 2027 expected | Her2-receptor negative breast cancer | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06355037 Background | May → Dec 2024 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06355024 Background | May 2024 → Jan 2025 | triple-negative breast carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT06099769 Comparator | Oct 2023 → Oct 2027 expected | breast cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05621434 Background | Dec 2022 → Dec 2024 | HER2 positive breast carcinoma | Fujian Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05570253 Background | Oct 2022 → Oct 2027 expected | triple-negative breast carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05420779 Comparator | Jun 2022 → Dec 2024 | breast carcinoma | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04986579 Background | Oct 2021 → Jun 2028 expected | breast cancer, chemotherapy-induced alopecia | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT04745975 Comparator | Feb 2021 → Jan 2023 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04681911 Background | Sep 2020 → Sep 2023 | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05530057 Comparator | Feb 2020 → Jun 2028 expected | breast cancer | Seoul National University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT03795012 Comparator | Apr 2019 → Mar 2021 | breast cancer | MedSIR | Terminated | No outcome recorded |
| Phase 2 | NCT02448420 Comparator | Jul 2015 → Sep 2023 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT02299999 Comparator | Apr 2014 → Dec 2022 overdue | breast cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01427933 Background | Nov 2011 → Sep 2013 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01104155 Comparator | Feb 2010 → Apr 2011 | non-small cell lung carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00879086 Comparator | Mar 2009 → Apr 2013 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00278993 Comparator | Jan 2006 → Jan 2008 | prostate cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 339 trials | ||||||
| Phase 3 | NCT07556848 Comparator | May 2026 → Dec 2027 expected | triple-negative breast carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07406542 Comparator | Apr 2026 → Apr 2029 expected | Her2-receptor negative breast cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07533123 Comparator | Mar 2026 → Mar 2029 expected | triple-negative breast carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07461454 Comparator | Mar 2026 → Dec 2027 expected | breast cancer | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07173751 Background | Oct 2025 → Dec 2029 expected | breast neoplasm | BioNTech SE | Recruiting | No outcome recorded |
| Phase 3 | NCT06732323 Comparator | Sep 2025 → Jun 2027 expected | triple-negative breast carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07047365 Background | Jul 2025 → Jun 2028 expected | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06957886 Comparator | May 2025 → May 2027 expected | breast carcinoma by gene expression profile | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06435429 Background | Aug 2024 → Apr 2028 expected | HER2 positive breast carcinoma | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06519370 Comparator | Aug 2024 → Aug 2026 overdue | triple-negative breast carcinoma | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06383767 Comparator | Jul 2024 → Jun 2027 expected | breast cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06263231 Comparator | Jun 2024 → Dec 2027 expected | soft tissue sarcoma | Intensity Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07371910 Comparator | Jun 2024 → Mar 2031 expected | Her2-receptor negative breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06255392 Comparator | Jun 2024 → Mar 2031 expected | Her2-receptor negative breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06279364 Comparator | Feb 2024 → Jul 2026 overdue | triple-negative breast carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06268652 Comparator | Jan 2024 → Feb 2026 overdue | breast carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06079983 Comparator | Dec 2023 → Apr 2026 overdue | breast cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT06081959 Comparator | Oct 2023 → Dec 2026 expected | breast cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06143553 Comparator | Sep 2023 → Dec 2025 overdue | breast cancer | Shanghai Yizhong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05814354 Comparator | Jun 2023 → Jan 2025 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05806060 Comparator | Apr 2023 → May 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05760378 Background | Mar 2023 → Jan 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05374512 Comparator | May 2022 → Aug 2025 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05134194 Background | Jan 2022 | triple-negative breast carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT05104866 Comparator | Oct 2021 → Jul 2024 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05346861 Background | Sep 2021 → Oct 2023 | HER2 positive breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT05063786 Comparator | Sep 2021 → Jun 2026 overdue | breast cancer | Spanish Breast Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04639986 Comparator | Nov 2020 → Dec 2026 expected | breast cancer | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03901339 Comparator | May 2019 → Oct 2023 | breast cancer | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03734029 Comparator | Dec 2018 → Jan 2022 overdue | breast cancer | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03262935 Comparator | Dec 2017 → Mar 2021 | breast cancer | Byondis B.V. | Completed | No outcome recorded |
| Phase 3 | NCT02574455 Comparator | Nov 2017 → Mar 2020 | breast cancer | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02915744 Comparator | Nov 2016 → Jul 2020 | breast cancer, metastatic neoplasm | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02555657 Comparator | Oct 2015 → Apr 2019 | triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02492711 Background | Aug 2015 → Aug 2021 | HER2 positive breast carcinoma, metastatic neoplasm | MacroGenics | Completed | No outcome recorded |
| Phase 3 | NCT02514681 Background | Aug 2015 → Dec 2018 | HER2 positive breast carcinoma | Japan Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT02000622 Comparator | Mar 2014 → Dec 2016 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01945775 Comparator | Oct 2013 → Sep 2017 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01492101 Comparator | Dec 2011 → Apr 2016 | female breast carcinoma | Nektar Therapeutics | Completed | No outcome recorded |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 254 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eribulin | “Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine,...” NCT01156753 ↗214“Participants will receive 6 cycles of a standard intravenous or oral chemotherapy regimen or an Antibody-Drug Conjugate (ADC), selected by the investigator from...” NCT07371910 ↗ “Eribulin mesylate (Halaven®) is a novel inhibitor of microtubule dynamics that has demonstrated a survival benefit in patients with locally recurrent or metastatic breast...” PMID 25242374 ↗ Sep 2014 “Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in...” NCT06072612 ↗ “The study is aimed to evaluate the efficacy of investigator's choice (ICC) of chemotherapy (nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone)...” NCT05954442 ↗ “Participants will receive investigator's choice of chemotherapy determined prior to randomization from 1 of the 4 allowed regimens as per protocol: eribulin, or vinorelbine or...” NCT07556848 ↗ “Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer...” NCT05621434 ↗ “One of the following Treatment of Physician Choice will be administered per standard of care: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel” NCT01492101 ↗ “A simulated dose reduction to eribulin 1.1 mg/m(2) in patients with moderate or severe renal impairment achieved the same exposure as 1.4 mg/m(2) in those with normal renal function.” PMID 26433580 ↗ Oct 2015 “PURPOSE: We report the dose-escalation part of a phase I study of liposomal eribulin (E7389-LF) in Japanese patients with advanced solid tumors and no alternative standard therapy.” PMID 35180771 ↗ May 2022 “Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs” NCT07047365 ↗ “Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.” NCT01698281 ↗ “E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor eribulin and has shown preliminary efficacy in the treatment of gastric cancer.” PMID 38295160 ↗ Apr 2024 “Palliative chemotherapy regimen includes Eribulin, Gemcitabine, Utidelone and Vinorelbine, by the treatment of physician's choice (TPC).” NCT06678048 ↗ “The chemotherapy regimen will consist of standard second-line agents such as capecitabine, eribulin, vinorelbine, or gemcitabine.” NCT07657130 ↗ “Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.” NCT03613181 ↗ “Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)” NCT06775236 ↗ “Chemotherapy of Physician's Choice, including nab-paclitaxel, Eribulin, Capecitabine, Vinorelbine, Gemcitabine.” NCT07203729 ↗ “Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy” NCT05346861 ↗ “Multimodal ablation combined with pucotenlimab and TPC or sacituzumab govitecan, eribulin,gemcitabine,UTD1” NCT06889610 ↗ “Eribulin mesylate (Halaven™, E7389) is a synthetic analog of the marine natural product halichondrin B” PMID 21887501 ↗ Sep 2011 “Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies” NCT01554371 ↗ “Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks” NCT04061863 ↗ “Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle.” NCT05347134 ↗ “or eribulin (1.4 mg/m\^2 intravenous on day 1 \& 8 of a 21 day cycle)” NCT01802970 ↗ “Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin” NCT06732323 ↗ “Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle” NCT02492711 ↗ “Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane” NCT02448420 ↗ “Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days” NCT02000622 ↗ “Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle” NCT06099769 ↗ “treated with eribulin in combination with erlotinib” NCT06678230 ↗ “Carboplatin, Eribulin, Pembrolizumab, Atezolizumab” NCT05774886 ↗ “Capecitabine, Eribulin, Gemcitabine or Vinorelbine” NCT01945775 ↗ “eribulin mesylate 1.4mg/m2 d1,8 iv, every 3 weeks” NCT05806060 ↗ “Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8” NCT04711824 ↗ “Eribulin 1.0 mg/m2, 2-5min iv before gemcitabine” NCT02263495 ↗ “Epirubicin, Eribulin, Erlotinib” NCT02788201 ↗ “Eribulin (Eri)” NCT03262935 ↗ “Drug: Eribulin” NCT03526679 ↗ “Eribulin” NCT05347134 ↗ |
| Known as | B-1939 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1683590 ↗ |
| Known as | E-7389 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1683590 ↗ |
| Known as | E7389 | “Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1...” NCT01126736 ↗18“Eribulin mesylate (E7389), a synthetic analog of the marine macrolide halichondrin B, is a microtubule inhibitor with a unique tubulin binding site and mechanism of action.” PMID 20450446 ↗ Jun 2010 “An Open-Label Phase I Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate (E7389) in Subjects With Advanced Solid Tumors” NCT03002493 ↗ “Eribulin mesylate (E7389) is a synthetic analog of Halichondrin B (HalB), a large polyether macrolide isolated from a marine sponge.” NCT01534455 ↗ “Eribulin mesylate (E7389) is a nontaxane microtubule dynamics inhibitor with a novel mechanism of action.” PMID 20299316 ↗ Apr 2010 “Eribulin mesylate (Halaven™, E7389) is a synthetic analog of the marine natural product halichondrin B” PMID 21887501 ↗ Sep 2011 “eribulin mesylate (E7389) has an impact on the electrocardiogram (ECG)” NCT01106248 ↗ “E7389 (Eribulin Mesylate)” NCT02225470 ↗ |
| Known as | E7389-LF | “PURPOSE: We report the dose-escalation part of a phase I study of liposomal eribulin (E7389-LF) in Japanese patients with advanced solid tumors and no alternative standard therapy.” PMID 35180771 ↗ May 2022 |
| Known as | ER-086526 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1683590 ↗ |
| Known as | Eribulin (as mesylate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1683590 ↗ |
| Known as | Eribulin (Eri) | “Eribulin (Eri)” NCT03262935 ↗ |
| Known as | Eribulin baxter | ChEMBL registry synonym — accepted as the source's own label CHEMBL1683590 ↗ |
| Known as | Eribulin Mcsilate | “Eribulin Mcsilate Injection” NCT07533123 ↗ |
| Known as | eribulin mesilate | “In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tumours received eribulin mesilate intravenously in 21-day cycles according to schedule 1...” PMID 30783204 ↗ Feb 20194“Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.” PMID 30928806 ↗ Mar 2019 “Eribulin mesilate 1.1mg/m2 i.v. will be administered intravenously every 3 weeks on day 1 and day 8 until progressive disease.” NCT02404506 ↗ “Eribulin mesilate is a non-taxane microtubule dynamics inhibitor with a novel mode of action.” PMID 21376385 ↗ Mar 2011 “patients to receive eribulin mesilate (1·4 mg/m(2) intravenously on days 1 and 8)” PMID 26874885 ↗ Feb 2016 |
| Known as | Eribulin mesiylate | “Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD” NCT02404506 ↗ |
| Known as | eribulin mesylate | “Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1...” NCT01126736 ↗52“Eribulin mesylate (Halaven®) is a novel inhibitor of microtubule dynamics that has demonstrated a survival benefit in patients with locally recurrent or metastatic breast...” PMID 25242374 ↗ Sep 2014 “To determine the safety and tolerability of everolimus and eribulin (eribulin mesylate), and determine the recommended Phase IB dose (RP2D) of the drug combination in patients...” NCT02120469 ↗ “This phase II trial is studying how well eribulin mesylate (E7389; Halichondrin B Analog) works in treating patients with metastatic prostate cancer that did not respond to...” NCT00337077 ↗ “Evaluate the antitumor activity of E7389 (eribulin mesylate), in terms of objective response rate, in patients with recurrent or progressive stage IIIB or IV non-small cell lung cancer.” NCT00400829 ↗ “Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.” NCT01458249 ↗ “After completion of 4 cycles of AC, each subject will begin 4 cycles of eribulin mesylate 1.4 mg/m2 intravenously over 2 to 5 minutes on Days 1 and 8 of every 21 day cycle.” NCT01328249 ↗ “Eribulin mesylate (E7389), a synthetic analog of the marine macrolide halichondrin B, is a microtubule inhibitor with a unique tubulin binding site and mechanism of action.” PMID 20450446 ↗ Jun 2010 “Eribulin Mesylate: A dose of 1.4 mg/m\^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.” NCT01142661 ↗ “Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying” NCT03051659 ↗ “Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.” PMID 21935916 ↗ Sep 2011 “Eribulin mesylate (E7389) is a synthetic analog of Halichondrin B (HalB), a large polyether macrolide isolated from a marine sponge.” NCT01534455 ↗ “Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer.” NCT01613768 ↗ “Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer” PMID 24699910 ↗ Apr 2014 “To evaluate the activity of eribulin (eribulin mesylate) in the management of advanced or recurrent cervical cancer” NCT01676818 ↗ “Eribulin mesylate 1.4 mg/m\^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.” NCT00965523 ↗ “Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2” NCT01744340 ↗ “Eribulin mesylate (E7389) is a nontaxane microtubule dynamics inhibitor with a novel mechanism of action.” PMID 20299316 ↗ Apr 2010 “Eribulin mesylate at the MTD for the selected schedule of dose escalation phase based on safety/PK data.” NCT01323530 ↗ “Eribulin mesylate (Halaven™, E7389) is a synthetic analog of the marine natural product halichondrin B” PMID 21887501 ↗ Sep 2011 “eribulin mesylate at 1.4 mg/m(2) intravenously (I.V.) on days 1 and 8 of each 21-day cycle” PMID 25024001 ↗ Jun 2014 “Eribulin mesylate is a halichondrin non-taxane inhibitor of microtubule dynamics.” PMID 29100193 ↗ Nov 2017 “Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial” PMID 33741296 ↗ Mar 2021 “Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection” NCT05420779 ↗ “eribulin mesylate (E7389) has an impact on the electrocardiogram (ECG)” NCT01106248 ↗ “Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate).” NCT04826016 ↗ “Eribulin mesylate injection, specification: 2ml: 1mg/piece.” NCT05263882 ↗ “Patients receive eribulin mesylate IV on days 1 and 8.” NCT00383760 ↗ “Eribulin mesylate is a potent microtubule inhibitor.” NCT05945368 ↗ “Eribulin mesylate (Halaven; Eisai Limited)” NCT02864030 ↗ “Eribulin mesylate 1.4 mg/m^2 intravenous” NCT01327885 ↗ “eribulin mesylate (eribulin)” NCT03361436 ↗ “Eribulin mesylate injection” NCT06079983 ↗ “E7389 (Eribulin Mesylate)” NCT02225470 ↗ “Drug: Eribulin Mesylate” NCT02097238 ↗ “Drug: Eribulin Mesylate” NCT02037529 ↗ “Drug: Eribulin mesylate” NCT01961544 ↗ “Drug: eribulin mesylate” NCT00047034 ↗ |
| Known as | Eribulin monomethanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1683590 ↗ |
| Known as | Eribulin: Halaven | “Eribulin: Halaven” NCT01802970 ↗ |
| Known as | Eribulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1683590 ↗ |
| Known as | Eribuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1683590 ↗ |
| Known as | Halaven | “Eribulin mesylate (Halaven®) is a novel inhibitor of microtubule dynamics that has demonstrated a survival benefit in patients with locally recurrent or metastatic breast...” PMID 25242374 ↗ Sep 20144“COMBINATION OF ERIBULIN (HALAVEN®) + BEVACIZUMAB (AVASTIN®) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER” NCT01941407 ↗ “Eribulin mesylate (Halaven™, E7389) is a synthetic analog of the marine natural product halichondrin B” PMID 21887501 ↗ Sep 2011 “Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle” NCT02492711 ↗ “Drug: Eribulin Injection [Halaven]” NCT05033769 ↗ |
| Known as | HALAVEN, Eribulin mesylate | “HALAVEN, Eribulin mesylate” NCT05810870 ↗ |
| Known as | Mevlyq | ChEMBL registry synonym — accepted as the source's own label CHEMBL1683590 ↗ |
| Known as | NSC# 707389 | “A Phase II Study of Eribulin (NSC# 707389) in Recurrent or Refractory Osteosarcoma” NCT02097238 ↗ |
| Action | Inhibit | “Eribulin mesylate is a tubulin inhibitor” PMID 21935916 ↗ Sep 2011 |
| Modality | Small molecule | “is a synthetic analog of the marine natural product halichondrin B” PMID 21887501 ↗ Sep 2011 |
| Route | Intravenous | “Given IV” NCT00047034 ↗ |